New hope for rare blood cancers: testing a powerful drug duo
NCT ID NCT07128381
Summary
This study is testing a new two-drug combination for adults with two rare and serious blood cancers: myelofibrosis (MF) and chronic myelomonocytic leukemia (CMML). The main goals are to find the safest and most effective dose of the new drug axatilimab, both alone and when added to an existing drug called ruxolitinib, and to see if this combination can help control these difficult-to-treat diseases. The trial will enroll about 66 people who have tried other treatments without success or who are newly diagnosed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.